Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall discussions reflect a strong recognition of the importance of including diverse populations in cancer trials, with comments highlighting that Lung-MAP enrolls more rural, older, or socioeconomically-deprived patients, citing phrases like 'a way forward' to indicate optimism about progress in equitable research. The tone emphasizes the significance of this progress but also hints at the need for continued efforts to improve representation among females and minorities.
Most discussions acknowledge that Lung-MAP improves diversity and represents a positive step in trial inclusivity, as seen with phrases like 'a way forward' and general consensus supporting broader participation.
The social discussions focus heavily on issues of diversity, access, and trial design, which are topics of high relevance and concern in current cancer research debates.
Many posts reference specific aspects of the study, such as increased enrollment of rural, older, or underserved populations, demonstrating active engagement and deeper analysis.
There is recognition that these findings could influence future trial designs and policies, although some posts imply that the change is ongoing and requires further action.
Clinical Trial #Diversity: A Bend in the Arc Toward Justice https://t.co/IQ6g9iVd7p @JCOPO_ASCO editorial says for medical evidence to be #equitable, we need fair #inclusion of underrepresented groups in trials: "Vaidya et al demonstrate a way forward" https://t.co/yLzWQBDJ9q
An @JCOPO_ASCO editorial commenting on @LungMAP paper by @riharv et al: Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP) https://t.co/2JULwhIjAv @FNIH_Org @SWOG @CancerResrch @NCICTEP_ClinRes @HosseinBorghaei @ReckampK https://t.co/BVDNk0l07W
Compared to conventional trials in advanced #NSCLC, biomarker-driven @LungMAP master protocol enrolled higher percentages of patients who are older, from rural or socioeconomically-deprived areas, or have Medicaid or no insurance. Analysis in @JCOPO_ASCO https://t.co/jGKC3H6Lp9
Dr. Mary Redman discusses the LungMAP protocol's efforts to include diverse lung cancer patients, highlighting increased access for older, rural, and socioeconomically disadvantaged groups, while emphasizing ongoing…
RT @LungMAP: Compared to conventional trials in advanced #NSCLC, biomarker-driven @LungMAP master protocol enrolled higher percentages of p…
RT @LungMAP: Compared to conventional trials in advanced #NSCLC, biomarker-driven @LungMAP master protocol enrolled higher percentages of p…
RT @LungMAP: Compared to conventional trials in advanced #NSCLC, biomarker-driven @LungMAP master protocol enrolled higher percentages of p…
Compared to conventional trials in advanced #NSCLC, biomarker-driven @LungMAP master protocol enrolled higher percentages of patients who are older, from rural or socioeconomically-deprived areas, or have Medicaid or no insurance. Analysis in @JCOPO_ASCO https://t.co/jGKC3H6Lp9
RT @JCOPO_ASCO:
RT @JCOPO_ASCO:
RT @LungMAP: An @JCOPO_ASCO editorial commenting on @LungMAP paper by @riharv et al: Representativeness of Patients Enrolled in the Lung…
RT @LungMAP: An @JCOPO_ASCO editorial commenting on @LungMAP paper by @riharv et al: Representativeness of Patients Enrolled in the Lung…
RT @LungMAP: An @JCOPO_ASCO editorial commenting on @LungMAP paper by @riharv et al: Representativeness of Patients Enrolled in the Lung…
RT @LungMAP: An @JCOPO_ASCO editorial commenting on @LungMAP paper by @riharv et al: Representativeness of Patients Enrolled in the Lung…
An @JCOPO_ASCO editorial commenting on @LungMAP paper by @riharv et al: Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP) https://t.co/2JULwhIjAv @FNIH_Org @SWOG @CancerResrch @NCICTEP_ClinRes @HosseinBorghaei @ReckampK https://t.co/BVDNk0l07W
RT @JCOPO_ASCO:
RT @JCOPO_ASCO:
RT @JCOPO_ASCO:
RT @JCOPO_ASCO:
RT @SWOG: Clinical Trial #Diversity: A Bend in the Arc Toward Justice https://t.co/IQ6g9iVd7p @JCOPO_ASCO editorial says for medical evide…
RT @SWOG: Clinical Trial #Diversity: A Bend in the Arc Toward Justice https://t.co/IQ6g9iVd7p @JCOPO_ASCO editorial says for medical evide…
RT @SWOG: Clinical Trial #Diversity: A Bend in the Arc Toward Justice https://t.co/IQ6g9iVd7p @JCOPO_ASCO editorial says for medical evide…
RT @SWOG: Clinical Trial #Diversity: A Bend in the Arc Toward Justice https://t.co/IQ6g9iVd7p @JCOPO_ASCO editorial says for medical evide…
RT @SWOG: Clinical Trial #Diversity: A Bend in the Arc Toward Justice https://t.co/IQ6g9iVd7p @JCOPO_ASCO editorial says for medical evide…
RT @SWOG: Clinical Trial #Diversity: A Bend in the Arc Toward Justice https://t.co/IQ6g9iVd7p @JCOPO_ASCO editorial says for medical evide…
Clinical Trial #Diversity: A Bend in the Arc Toward Justice https://t.co/IQ6g9iVd7p @JCOPO_ASCO editorial says for medical evidence to be #equitable, we need fair #inclusion of underrepresented groups in trials: "Vaidya et al demonstrate a way forward" https://t.co/yLzWQBDJ9q
Date of Publication: 2023 Sep https://t.co/QjQpaWGeTG #Medicaid
Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). (JCO Precis Oncol)